- Home
- KIDS vs RIGL Comparison
KIDS vs RIGL Comparison
Compare KIDS & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIDS
- RIGL
- Stock Information
- Founded
- KIDS 2007
- RIGL 1996
- Country
- KIDS United States
- RIGL United States
- Employees
- KIDS N/A
- RIGL N/A
- Industry
- KIDS Medical/Dental Instruments
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- KIDS Health Care
- RIGL Health Care
- Exchange
- KIDS Nasdaq
- RIGL Nasdaq
- Market Cap
- KIDS 524.3M
- RIGL 537.6M
- IPO Year
- KIDS 2017
- RIGL 2000
- Fundamental
- Price
- KIDS $16.31
- RIGL $46.01
- Analyst Decision
- KIDS Strong Buy
- RIGL Strong Buy
- Analyst Count
- KIDS 7
- RIGL 5
- Target Price
- KIDS $24.86
- RIGL $43.20
- AVG Volume (30 Days)
- KIDS 185.7K
- RIGL 680.3K
- Earning Date
- KIDS 10-28-2025
- RIGL 11-04-2025
- Dividend Yield
- KIDS N/A
- RIGL N/A
- EPS Growth
- KIDS N/A
- RIGL 2698.26
- EPS
- KIDS N/A
- RIGL 6.20
- Revenue
- KIDS $227,410,000.00
- RIGL $282,076,000.00
- Revenue This Year
- KIDS $16.58
- RIGL $59.93
- Revenue Next Year
- KIDS $12.46
- RIGL N/A
- P/E Ratio
- KIDS N/A
- RIGL $7.46
- Revenue Growth
- KIDS 19.90
- RIGL 79.13
- 52 Week Low
- KIDS $15.28
- RIGL $14.63
- 52 Week High
- KIDS $27.60
- RIGL $46.30
- Technical
- Relative Strength Index (RSI)
- KIDS 40.96
- RIGL 76.09
- Support Level
- KIDS $16.04
- RIGL $34.00
- Resistance Level
- KIDS $17.19
- RIGL $39.56
- Average True Range (ATR)
- KIDS 0.58
- RIGL 2.68
- MACD
- KIDS 0.05
- RIGL 1.31
- Stochastic Oscillator
- KIDS 31.19
- RIGL 97.69
About KIDS OrthoPediatrics Corp.
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.